- Home
- ORIC vs PEB Comparison
ORIC vs PEB Comparison
Compare ORIC & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | PEB |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ORIC | PEB |
|---|---|---|
| Price | $12.06 | $11.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $19.73 | $12.35 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,464,126,000.00 |
| Revenue This Year | N/A | $2.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.99 |
| 52 Week Low | $3.90 | $7.42 |
| 52 Week High | $14.93 | $14.21 |
Technical Indicators
Market Signals| Indicator | ORIC | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 46.63 |
| Support Level | $11.52 | $11.81 |
| Resistance Level | $12.61 | $12.79 |
| Average True Range (ATR) | 0.83 | 0.43 |
| MACD | 0.33 | -0.06 |
| Stochastic Oscillator | 86.92 | 11.15 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.